Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXTBiotechnology
+$0.46 today
- Market cap
- $89.11M
- Beta
- 1.05
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$0.67
Volume 0.61M
Average 0.12M
LIXT Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Lixte Biotechnology Holdings, Inc.NASDAQ: LIXT
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation outflow shrinks to $0
Q1 FY2026 stock-based compensation was $0, compared with $99.74K a year earlier. Trailing-twelve-month stock-based compensation was $1.46M. Over 3 fiscal years it compounded at +0.3% a year.
Context
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $365.05K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 1.56M USD
- Year-over-year change
- +272.8%
- 4-year CAGR
- -12.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.56M | +272.8% |
| FY2024 | 2024-12-31 | 418.42K | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 1.55M | -40.5% |
| FY2021 | 2021-12-31 | 2.6M | — |
Stock-Based Compensation vs competitors
How LIXT compares with its peers on the latest reported figures
- LIXT's LTM Mar 2026 stock-based compensation of $1.46M is the smallest of the 2 companies compared; the peer median is $1.76M.
- Its year-over-year change of +333.0% is the highest of 2, against a peer median of -99.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.76M | -99.8% | — | — | |
| LTM Mar 2026 | $1.46M | +333.0% | +0.3% | — | |
| Peer median (excluding LIXT) | $1.76M | -99.8% | — | — | |
Competitors are the stored peer set for LIXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXT
Intrinsic Alpha fair value
Locked
Current Price
$7.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.